Search
Menu
DataRay Inc. - ISO 11146-Compliant Laser Beam Profilers

Axcan Acquires Photofrin Rights from QLT

Facebook X LinkedIn Email
MONT SAINT-HILAIRE, Quebec, Canada, May 2 -- Axcan Pharma Inc. has signed an agreement to acquire worldwide rights to Photofrin -- a drug approved for use in photodynamic therapy for the treatment of certain cancers -- from QLT PhotoTherapeutics Inc. (QLT) of Vancouver.
Axcan's acquisition of the rights to the drug involves a stock subscription agreement under which QLT will purchase 1,283,333 shares of Axcan common stock for $19,250,000 (CDN), or $15 per share (CDN). The transaction between the two companies also involves an asset purchase agreement, which calls for QLT to sell, license or sub-license to Axcan all QLT's rights, title and interest in Photofrin for $39.25 million (CDN). This agreement includes the sale of QLT's European subsidiary, which owns the European registrations for Photofrin.
LPC/Photonics.com - Newest Webinars on Demand

Published: May 2000
News & Features

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.